Trial Outcomes & Findings for Shared Healthcare Actions and Reflections Electronic Systems in Survivorship (NCT NCT04337203)

NCT ID: NCT04337203

Last Updated: 2023-06-28

Results Overview

Using a 95% confidence interval (CI) to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to be referred to SHARE-S.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

40 participants

Primary outcome timeframe

1 year, 8 months

Results posted on

2023-06-28

Participant Flow

Participant milestones

Participant milestones
Measure
SHARE-S Intervention
SHARE-S Intervention
Overall Study
STARTED
40
Overall Study
COMPLETED
40
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Shared Healthcare Actions and Reflections Electronic Systems in Survivorship

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Single Arm
n=40 Participants
Intervention
Age, Continuous
57.4 years
STANDARD_DEVIATION 15.7 • n=5 Participants
Sex: Female, Male
Female
29 Participants
n=5 Participants
Sex: Female, Male
Male
11 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
39 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
1 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
9 Participants
n=5 Participants
Race (NIH/OMB)
White
29 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
BMI, Continuous
32.2 Kg/m^2
STANDARD_DEVIATION 6.8 • n=5 Participants
Marital Status, Categorical
Currently Married
28 Participants
n=5 Participants
Marital Status, Categorical
Separated
1 Participants
n=5 Participants
Marital Status, Categorical
Divorced
3 Participants
n=5 Participants
Marital Status, Categorical
Widowed
2 Participants
n=5 Participants
Marital Status, Categorical
Single, never married
5 Participants
n=5 Participants
Marital Status, Categorical
Prefer not to answer
1 Participants
n=5 Participants
Highest Grade, Categorical
8th to 11th grade
1 Participants
n=5 Participants
Highest Grade, Categorical
High school or equivalent
5 Participants
n=5 Participants
Highest Grade, Categorical
Vocation/technical school post HS
1 Participants
n=5 Participants
Highest Grade, Categorical
Associate's degree/some college
8 Participants
n=5 Participants
Highest Grade, Categorical
Bachelor's degree
17 Participants
n=5 Participants
Highest Grade, Categorical
Graduate or professional school
8 Participants
n=5 Participants
Primary Tumor Site, Categorical
Breast
18 Participants
n=5 Participants
Primary Tumor Site, Categorical
Colorectal
1 Participants
n=5 Participants
Primary Tumor Site, Categorical
Endometrial
3 Participants
n=5 Participants
Primary Tumor Site, Categorical
Non-Hodgkin Lymphoma
1 Participants
n=5 Participants
Primary Tumor Site, Categorical
Prostate
10 Participants
n=5 Participants
Primary Tumor Site, Categorical
Other
7 Participants
n=5 Participants
History of Cancer-Related Surgical Procedure, Categorical
Yes
25 Participants
n=5 Participants
History of Cancer-Related Surgical Procedure, Categorical
No
15 Participants
n=5 Participants
History of Radiation Therapy, Categorical
Yes
28 Participants
n=5 Participants
History of Radiation Therapy, Categorical
No
12 Participants
n=5 Participants
History of Chemotherapy, Categorical
Yes
18 Participants
n=5 Participants
History of Chemotherapy, Categorical
No
22 Participants
n=5 Participants
Time since last treatment/surgery (months)
5 months
n=5 Participants
Difficult to pay monthly bills, Categorical
Very difficult
2 Participants
n=5 Participants
Difficult to pay monthly bills, Categorical
Somewhat difficult
8 Participants
n=5 Participants
Difficult to pay monthly bills, Categorical
Not very difficult
16 Participants
n=5 Participants
Difficult to pay monthly bills, Categorical
Not at all difficult
14 Participants
n=5 Participants
Travel to clinic bills (minutes)
31.5 minutes
STANDARD_DEVIATION 28.6 • n=5 Participants
Use internet or email at least occasionally, Categorical
Yes
38 Participants
n=5 Participants
Use internet or email at least occasionally, Categorical
No
2 Participants
n=5 Participants
Confident filling out medical forms, Categorical
Extremely
27 Participants
n=5 Participants
Confident filling out medical forms, Categorical
Quite a bit
11 Participants
n=5 Participants
Confident filling out medical forms, Categorical
Somewhat
2 Participants
n=5 Participants
Confident filling out medical forms, Categorical
A little bit
0 Participants
n=5 Participants
Confident filling out medical forms, Categorical
Not at all
0 Participants
n=5 Participants
Number of times received income assistance, Categorical
Never
30 Participants
n=5 Participants
Number of times received income assistance, Categorical
Once
4 Participants
n=5 Participants
Number of times received income assistance, Categorical
Twice
4 Participants
n=5 Participants
Number of times received income assistance, Categorical
Three times
1 Participants
n=5 Participants
Number of times received income assistance, Categorical
Four times
0 Participants
n=5 Participants
Number of times received income assistance, Categorical
More than four times
1 Participants
n=5 Participants
Rural residence, Categorical
Yes
5 Participants
n=5 Participants
Rural residence, Categorical
No
35 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 year, 8 months

Population: Total number reflects the total number of participants who were electronically referred in SHARE-S intervention.

Using a 95% confidence interval (CI) to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to be referred to SHARE-S.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=118 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Number of Patients Enrolled Out of Those Electronically Referred
40 number of participants
Interval 29.0 to 50.0

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: Total number given a care plan

Using a 95% confidence interval to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to enroll in SHARE-S

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=409 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Adoption - Number of Electronically Referred Patients - Those Possible [Based on Chart Review]
118 Participants

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: Initial cohort less 6 lost to follow-up at time of subsequent survey administration

This measure will be used along with qualitative feedback among participants using a mixed-methods to assess acceptability of intervention with different cancer types. Acceptability ranges from 1-5 with higher scores indicating more acceptability.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=34 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Acceptability of Intervention Measure
4.4 score on a scale
Standard Deviation .6

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: Initial cohort less 6 lost to follow-up at time of subsequent survey administration

This measure will be used along with qualitative feedback among participants using a mixed-methods to assess appropriateness of intervention with different cancer types. Appropriateness ranges from 1-5 with higher scores meaning more appropriateness.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=34 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Appropriateness of Intervention Measure
4.3 score on a scale
Standard Deviation 0.6

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: Number enrolled per month.

This will be defined as the average number of participants that enroll per month that the study is open to enrollment.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Number of Participants Enrolled Per Month
2 participants/month
Interval 0.0 to 7.0

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: Initial cohort less 6 lost to follow-up at time of subsequent survey administration

This measure will be used along with qualitative feedback among participants using a mixed-methods to assess feasibility of intervention with different cancer types. Feasibility ranges from 1-5 with higher scores indicating more feasibility.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=34 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Feasibility of Intervention Measure
4.3 score on a scale
Standard Deviation .5

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: SHARE-S Intervention enrolled participants less 5 lost in follow-up.

Retention is defined as participants that complete the follow up assessment.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Retention Rates
35 Participants

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: 40 enrolled

Defined as participants that adhere to responding to text messages received during intervention.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Number of Participants Adhering to Text Responses
27 Participants

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: 40 enrolled

Defined as adherence to completing coaching sessions during the intervention.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Participant Adherence to Coaching Sessions
36 Participants

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: 40 enrolled (mean minutes over coach calls at 3 timepoints).

Defined as how long each completed coaching sessions lasted during the intervention.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Length of Coaching Sessions
39 minutes
Interval 7.0 to 69.0

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: 40 enrolled

Defined as an observational checklist completed for a subset of coaching sessions.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Number of Coaching Sessions Completed
111 sessions

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: 40 participants enrolled

Number of patients enrolled will be defined as overall participants for the entirety of the study.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Total Number of Patients Enrolled
40 Participants

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: 40 participants enrolled

Adverse events related to the intervention will be assessed in adverse event log.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Frequency of Adverse Events
0 events

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: Initial cohort with 6 lost to follow-up at time of subsequent survey administration

Patient reported measure of patient-centered communication/relatedness completed only at follow-up. Range 0-35 with higher scores indicating better communication.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=34 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
HEAL Patient-Provider Connection
32.3 score on a scale
Standard Deviation 4.2

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 enrolled at baseline; 35 available at follow-up

Questionnaire to assess the social role (0-100), physical functioning (0-100), anxiety (0-100), depression (0-100), fatigue (0-100), sleep disturbance (0-100), pain interference (0-100), pain intensity (0-10). Lower scores indicate less of construct.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=35 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Patient-Reported Health Outcomes PROMIS Profile 29
physical function (0-100)
48.4 score on a scale
Standard Deviation 8.2
49.2 score on a scale
Standard Deviation 8.5
Patient-Reported Health Outcomes PROMIS Profile 29
anxiety (0-100)
50.6 score on a scale
Standard Deviation 9.8
49.0 score on a scale
Standard Deviation 8.5
Patient-Reported Health Outcomes PROMIS Profile 29
depression (0-100)
48.1 score on a scale
Standard Deviation 9.3
45.9 score on a scale
Standard Deviation 7.7
Patient-Reported Health Outcomes PROMIS Profile 29
fatigue (0-100)
51.3 score on a scale
Standard Deviation 10.9
49.2 score on a scale
Standard Deviation 11.5
Patient-Reported Health Outcomes PROMIS Profile 29
sleep disturbance (0-100)
49.6 score on a scale
Standard Deviation 7.4
48.9 score on a scale
Standard Deviation 6.3
Patient-Reported Health Outcomes PROMIS Profile 29
social roles (0-100)
51.2 score on a scale
Standard Deviation 9.4
54.2 score on a scale
Standard Deviation 10.8
Patient-Reported Health Outcomes PROMIS Profile 29
pain interference (0-100)
51.5 score on a scale
Standard Deviation 10.2
50.3 score on a scale
Standard Deviation 9.3
Patient-Reported Health Outcomes PROMIS Profile 29
pain intensity (0-10)
2.7 score on a scale
Standard Deviation 2.4
2.5 score on a scale
Standard Deviation 2.4

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 enrolled at baseline; 35 answered follow-up questionnaire

Participants will only answer the single item question that provides an indication of perceived change in health. Score range: 1 - excellent health, 2 - very good health, 3 - good health, 4 - fair health and 5 - poor health.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=35 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
36-Item Short Form Survey (SF-36)
3.15 score on a scale
Standard Deviation 0.83
3.15 score on a scale
Standard Deviation 0.89

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 participants at baseline; 35 participants answered follow-up questionnaire

Investigators will only assess the quality of life of adult cancer survivors measuring domains of cancer survivorship that are cancer-specific. Cancer-Specific Quality of Life (range 15-105) - higher score indicates more quality of life; Benefits of Having Cancer (range 4-28) - higher score indicates more benefits; Positive Feelings (range 4-28) - lower score indicates more positive feelings.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=35 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Cancer-specific Quality of Life in Adult Cancer Survivors (QLACS) Questionnaire
Cancer-Specific Quality of Life
47 score on a scale
Standard Deviation 20.5
40.9 score on a scale
Standard Deviation 19.1
Cancer-specific Quality of Life in Adult Cancer Survivors (QLACS) Questionnaire
Benefits of Having Cancer
13.9 score on a scale
Standard Deviation 5.8
12.2 score on a scale
Standard Deviation 5.7
Cancer-specific Quality of Life in Adult Cancer Survivors (QLACS) Questionnaire
Positive Feelings
10.6 score on a scale
Standard Deviation 5.4
9.5 score on a scale
Standard Deviation 4.3

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 participants at baseline; 35 participants answered follow-up questionnaire

The Index of Autonomous Functioning - self congruence subscale only. 5 Items were paired with a Likert-type scale with 1 = "not at all true", 2 = "a bit true", 3 = "somewhat true", 4 = "mostly true", and 5 = "completely true." Mean score is average of 5 items. Higher mean score indicate a higher level of self congruence functioning.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=35 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Index of Autonomous Functioning - Self Congruence Subscale Only
4.3 score on a scale
Standard Deviation .5
4.3 score on a scale
Standard Deviation .6

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 participants at baseline; 35 participants answered follow-up questionnaire

A questionnaire made up of 6-items on a visual analog scale, ranging from 1 (not at all confident) to 10 (totally confident). Higher the mean score indicates higher self-efficacy.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=35 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Self-Efficacy to Manage Chronic Disease Questionnaire
7.7 score on a scale
Standard Deviation 1.8
7.8 score on a scale
Standard Deviation 1.9

SECONDARY outcome

Timeframe: 1 year, 8 months

Population: 34 participants available at follow-up

Self-reported use of the care plan since enrolled on the study.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=34 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Engagement With the Survivorship Care Plan
34 Participants

SECONDARY outcome

Timeframe: Up to 30 days after the final intervention session.

Population: Follow-up only

Participants will evaluate their overall satisfaction with their care after the study intervention. Mean of Likert scale. 1=very poor, 5=very good.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=35 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Satisfaction of Care
4.8 score on a scale
Standard Deviation .4

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: 40 participants at baseline; 34 participants answered follow-up questionnaire

Participants will be asked about their tobacco use within the last seven days. Tobacco use is scored 1=yes, 0=no. Higher values represent more participants were tobacco users.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=34 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Health Behaviors Questionnaire - Tobacco Use
1 Participants
1 Participants

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: Entire cohort at baseline; 34 participants at follow-up.

Participants will be asked individual questions about their alcohol use. Alcohol use disorder is on a scale of 0-12 with higher scores indicating more hazardous; men ≥ 4, women ≥ 3 is considered hazardous.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=34 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Health Behaviors Questionnaire - Alcohol Use Disorder
1.4 score on a scale
Standard Deviation 1.9
1.2 score on a scale
Standard Deviation 1.6

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: Entire cohort at baseline; 34 participants at follow-up.

Participants will be asked individual questions about their physical activity. Physical activity is minutes/week with \<90 minutes considered insufficient.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=34 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Health Behaviors Questionnaire - Physical Activity
124.5 minutes/week
Standard Deviation 140
162.4 minutes/week
Standard Deviation 157.2

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: Entire cohort at baseline; 34 participants at follow-up.

Participants will be asked individual questions about their fruit and vegetable intake. Mean for the responses were calculated in cups so ½ to 1 cup = 0.75 cups, at least 2-3 cups for both considered sufficient.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=34 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Health Behaviors Questionnaire - Fruit and Vegetable Intake
2.7 cups/day
Standard Deviation 1.2
3.2 cups/day
Standard Deviation 1.6

SECONDARY outcome

Timeframe: At baseline and up to 30 days after the final intervention session.

Population: Entire cohort at baseline; 34 participants at follow-up.

Participants will be asked individual questions how many days/week they practice mindfulness.

Outcome measures

Outcome measures
Measure
SHARE-S Intervention
n=40 Participants
Enrolled in intervention
SHARE-S Intervention - Follow-Up
n=34 Participants
Same cohort with 5 lost to follow-up at time of subsequent survey administration
Health Behaviors Questionnaire - Mindfulness Practice
1.8 days/week
Standard Deviation 2.1
3.4 days/week
Standard Deviation 2.1

Adverse Events

Overall

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Carol Kittel

Wake Forest Baptist Comprehensive Cancer Center

Phone: 336-399-3832

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place